What is the market's earnings forecast for Aflac next quarter?

What is the revenue and EPS growth rate for Aflac year over year?

What were the key takeaways from Aflac's earnings call?

What is Aflac's gross profit margin?

What were the key takeaways from Aflac’s earnings call?

Did Aflac beat or miss consensus estimates last quarter?

What is Aflac's latest dividend and current dividend yield?

What does Aflac do and what are its main business segments?

- **Japan Growth**: 16% annual sales driven by Miraito (35.6% growth) and Anshin Palette, with 93.1% persistency. U.S. delivered $1.6B new sales, 2.9% net earned premium growth.
- **Financial Strength**: $3.5B buybacks, 5.2% dividend increase. Japan pretax margin 31.3%, U.S. 17.4%.
- **Risks & Strategy**: Japan savings products may see lapses with rising rates. U.S. scaling group life/disability (4% growth) offsets core business slowdown. AI pilot in claims automation.

**【CEO Summary Section】**
- Aflac Japan achieved 15.7% Q4 and 16% annual sales growth in 2025, driven by Miraito cancer insurance (35.6% sales growth) and new medical product Anshin Palette. Japan's premium persistency remained strong at 93.1%, offsetting lapses from product launches. U.S. generated $1.6B in new sales, with 2.9% net earned premium growth and 79.2% persistency. The company repurchased $3.5B in shares and increased dividend by 5.2% in 2025.

**【CFO Financial Commentary】**
- Q4 2025 adjusted EPS was $1.57, with Japan segment net earned premiums down 1.9% in yen terms. U.S. segment net earned premiums grew 4%, but benefit ratio rose 230bps to 48.6% due to claims activity and new business scaling. Japan's pretax margin was 31.3%, while U.S. margin was 17.4%. The company repurchased $800M of stock in Q4 and maintained $4.1B unencumbered liquidity.

**【Q&A Highlights】**
- Japan's savings products may face higher surrenders due to rising interest rates, but persistency remains stable. U.S. group life/disability sales grew 11.3%, offsetting slower core voluntary benefits growth. AI is being tested in claims automation and enrollment processes, but no material impact yet. Capital deployment remains disciplined, with no immediate M&A plans despite regulatory flexibility.

Aflac Incorporated (AFL) Q4 2025 Earnings Call Transcript

- **Financial Strength**: Adjusted EPS up 15% to $2.49, driven by $580M remeasurement gains.
- **Japan Growth**: Underlying earned premiums down 1.2%, but pretax margin 52.2% (750bp YoY increase).
- **U.S. Efficiency**: Pretax margin 21.7% (90bp YoY increase), offsetting $21M one-time contract fee.
- **Capital Discipline**: $1B stock buyback, 22% leverage ratio, SMR >900%, ESR >250%.

**【CFO Financial Commentary】**
- **Adjusted EPS**: $2.49 (15% YoY increase), driven by $580M remeasurement gains and $55M deferred profit liability increase.
- **Japan Segment**: 
  - Net earned premiums declined 4% (underlying -1.2%), benefit ratio 39.3% (10% YoY improvement), persistency 93.3%.
  - Expense ratio 19.8% (20bp YoY decline), pretax margin 52.2% (750bp YoY increase).
- **U.S. Segment**: 
  - Net earned premiums up 2.5%, benefit ratio 45.6% (200bp YoY improvement).
  - Expense ratio 38.9% (90bp YoY increase) due to $21M one-time contract termination fee.
  - Pretax margin 21.7% (90bp YoY increase), adjusted net investment income up 1.9%.
- **Corporate & Other**: 
  - Pretax earnings $69M, adjusted net investment income $66M (6% YoY increase).
  - CECL reserves increased by $28M (commercial real estate) and $7M (middle market loans).
  - Liquidity $4.5B (270% above minimum), leverage 22% (within 20-25% target).
- **Capital Deployment**: 
  - Repurchased $1B stock, paid $9M dividends, maintaining strong capital ratios (SMR >900%, ESR >250%).
  - 2025 guidance: Japan pretax margin 35-38%, U.S. pretax margin 17-20% range upper end.

Aflac Incorporated (AFL) Q3 2025 Earnings Call Transcript

- **Japan Sales Surge**: 23.2% YoY growth, 53% cancer insurance boost from Miraito, targeting pre-pandemic sales recovery.
- **U.S. Stability**: 2.7% sales growth, 3.4% earned premium rise, strong persistency at 79.2%.
- **Capital Strength**: $1.1B returned to shareholders, SMR >900%, RBC >600%, $5.1B liquidity.
- **Investment Performance**: Japan NII up on variable gains, U.S. NII down 5% but core portfolio resilient.
- **Strategic Initiatives**: Digitization in Japan, agile product teams, and disciplined underwriting driving long-term growth.

**【CEO Summary Section】**
- **Japan Performance**: Q2 sales increased 23.2% YoY, driven by 53% growth in cancer insurance sales, particularly the Miraito product. Aflac Japan maintained strong persistency at 93.7% and introduced Tsumitasu, a third-sector product targeting younger customers. The company aims to recover to pre-pandemic sales levels.
- **U.S. Growth**: U.S. sales rose 2.7% YoY, with net earned premium up 3.4% and persistency at 79.2%. Group life/disability and network dental showed momentum, supported by disciplined underwriting.
- **Capital Deployment**: Deployed $829M in share buybacks and paid $312M in dividends, emphasizing shareholder returns while maintaining strong capital ratios (SMR >900%, RBC >600%).

**【CFO Financial Commentary】**
- **Japan Financials**: Adjusted EPS $1.78 (down 2.7% YoY), with Japan's pretax margin at 32% despite 20.6% expense ratio. Net investment income (NII) in yen declined 10.5% due to lower floating rates, but variable NII improved on portfolio marks.
- **U.S. Performance**: U.S. pretax margin 22.5%, driven by 36.3% expense ratio (down 60bps YoY). Group business growth added 70bps to expense ratio, expected to decline as scale improves.
- **Investment Strategy**: Raised $1B in yen debt to prefund 2026 maturities, increasing unencumbered liquidity to $5.1B. Japan's ESR (economic surplus ratio) at 240% reflects strong capital management.

**【Q&A Highlights】**
- **Cancer Sales Sustainability**: Miraito's flexible design and exclusive consultation service drove 53% cancer sales growth. Management expects sustained momentum, with potential for longer-term benefits.
- **NII Trends**: Japan's Q2 NII benefited from variable portfolio gains and make-whole calls. U.S. NII declined 5% due to lower floating rates, but core portfolio performance remained solid.
- **Expense Management**: Japan's expense ratio up 280bps YoY due to tech investments; U.S. expenses optimized through scale and efficiency.
- **Capital Allocation**: Buybacks and dividends prioritized, with M&A potential if strategic opportunities arise. Holdco liquidity ($5.1B) provides flexibility for future deployments.
- **Product Refresh Cycle**: Japan plans 2-year medical product refreshes and 3-year cancer product updates, subject to FSA approval. Tsumitasu's stable returns attract younger customers despite market volatility.

Aflac Incorporated (AFL) Q2 2025 Earnings Call Transcript

- **Japan Outperformance**: 12.6% sales growth led by cancer insurance, new Miraito product on track for 2025 sales beat.
- **US Profitability**: 3.5% sales growth with 20.8% pretax margin, despite macro headwinds.
- **Capital Efficiency**: $1.2B returned to shareholders via buybacks and dividends, maintaining >950% SMR.
- **FX Resilience**: Hedged program limits Yen volatility impact, ESR >250% with 25-30% OTM put protection.
- **Growth Drivers**: Japan cancer product adoption (50% new customers), US dental recovery (+23% Q1 sales).

**【CEO Overview】**
- **Japan Sales Growth**: 12.6% YoY driven by Tsumitasu cancer insurance, with 6.3% increase from cancer policies. New Miraito product launched in March shows early success, available across all channels as of April 21.
- **US Momentum**: 3.5% YoY sales growth, strong performance in group life/disability and network dental. Adjusted EPS unchanged at $1.66 despite $0.05 impact from investment losses.
- **Capital Deployment**: $900M share buyback and $317M dividends in Q1, total $1.2B returned to shareholders.

**【CFO Financial Details】**
- **Japan Segment**: 
  - Net earned premiums down 5%, but underlying earned (adjusted for reinsurance) down 1.4%.
  - Benefit ratio 65.8% (-120bps YoY), persistency 93.8% (+40bps YoY).
  - Expense ratio 19.6% (+160bps YoY) due to tech investments.
- **US Segment**: 
  - Net earned premiums +1.8%, persistency 79.3% (+60bps YoY).
  - Benefit ratio 47.7% (+120bps YoY), expense ratio 37.6% (-110bps YoY).
  - Pretax margin 20.8% (-20bps YoY) despite lower floating rate income.
- **Liquidity & Capital**: 
  - $4.3B unencumbered liquidity, SMR >950%, RBC >600%, ESR >250%.
  - $25.5B unhedged USD assets in Japan, hedged with $2.7B forwards and $4.4B Yen debt.

**【Key Q&A Takeaways】**
- **Yen Sensitivity**: Every ¥5 move impacts EPS ~$0.07. Current hedging program (including 25-30% OTM puts) limits tail risk while maintaining upside.
- **Japan Cancer Product**: Miraito sales ramping up, 2025 sales expected to exceed 2024 levels. Tsumitasu now sold to 50% of new customers.
- **US Dental Recovery**: Q1 sales +23%, agents selling dental see 20% overall sales boost. Platform stabilization and broker partnerships driving momentum.
- **Investment Income Pressure**: Floating rate headwinds (~100bps YoY decline) offset by higher private credit returns and strategic portfolio repositioning.
- **Macro Resilience**: Strong capital ratios (SMR 950%+, RBC >600%) and tactical hedging maintain risk-adjusted ROE spread to cost of capital.

Aflac (AFL)-1 May 25-2025 Q1 Earnings call transcript

- **Japan Dominance**: 36% pretax margin in 2024, 5.6% sales growth, and Sumitas driving younger customer acquisition.
- **US Resilience**: 2.7% premium growth, 79.3% persistency, but Q4 sales drag from dental platform challenges.
- **Capital Return**: $3.9B returned to shareholders in 2024, including $750M Q4 buybacks.
- **Key Risks**: Floating rate headwinds in 2025, slow CRE recovery, and competitive US market dynamics.
- **Growth Catalysts**: Japan's new cancer product (Q2 2025) and US dental platform stabilization.


**【CEO Summary Section】**
- **Japan Dominance**: Aflac Japan contributed 70% of pretax adjusted earnings and 75% of the consolidated balance sheet in 2024, with a record 36% pretax profit margin. Sales increased 5.6% YoY, driven by Sumitas product adoption among younger customers.
- **US Resilience**: Aflac U.S. saw net earned premiums grow 2.7%, with a 70bp improvement in premium persistency to 79.3%. However, Q4 sales underperformed due to dental platform stabilization and competitive pressures.
- **Capital Deployment**: Returned $3.9B to shareholders via buybacks and dividends in 2024, with $750M repurchased in Q4. 2024 also marked the 42nd consecutive year of dividend growth.

**【CFO Financial Commentary】**
- **Japan Financials**: Q4 adjusted EPS grew 24.8% to $1.56, driven by Japan's 31.6% pretax margin. Net investment income in yen rose 3.7%, offsetting reinsurance transaction impacts. Full-year pretax margin hit 36%, a 30-year high.
- **US Performance**: U.S. pretax margin was 19.7% in Q4, with a 310bp expense ratio decline to 38.5% annually. Dental sales lagged (33% Q4 decline), but group life and disability lines showed promise.
- **Investment Challenges**: Commercial real estate CECL reserves increased by $40M, reflecting ongoing market distress. Floating rate income headwinds from lower SOFR rates expected to impact 2025 NII.

**【Q&A Key Themes】**
- **US Sales Struggles**: Dental platform recovery lagged due to broker skepticism, but new cancer product launch (Q2 2025) and improved dental platform execution could drive 2025 growth.
- **Japan Growth Drivers**: Sumitas sales and new cancer product (March 2025) targeting younger customers. Expense ratio optimization and reinsurance efficiency support margin resilience.
- **Capital Strategy**: Share buybacks (e.g., $750M in Q4) prioritized over dividend hikes, with focus on organic growth through disciplined underwriting.
- **Risk Management**: Commercial real estate recovery expected to be slow, with CECL reserves and REO management maintaining capital strength.


Aflac (AFL)-6 Feb 25-2024 Q4 Earnings call transcript

- **Japan Sales Surge**: 12.3% YoY growth from Tsumitas launch, with 20-25% new customer mix and 50th anniversary cross-selling opportunities.
- **US Profitability**: 20.8% pretax margin driven by expense management and 5.5% QoQ sales growth in group life and cancer insurance.
- **Capital Deployment**: $500M Q3 buybacks + $280M dividends, with flexibility for M&A or special dividends if warranted.
- **Risk Management**: Solid portfolio performance with $1B CRE watch list, $3M CECL reserve increase, and no Japan FSA impairments.
- **Leadership Strength**: Promoted executives (Miller, Broden, Tillman) driving strategic initiatives amid aging Japan population and US market competition.

**【CEO Overview】**
- **Japan Market Growth**: Q3 sales up 12.3% YoY, driven by Tsumitas product launch targeting younger customers. Cancer insurance sales via Japan Post channel remain strong despite 2+ years in market.
- **US Market Resilience**: US sales grew 5.5% QoQ, with strong performance in group life, absence management, and cancer insurance. 20.8% pretax profit margin reflects disciplined expense management.
- **Investment Strategy**: Maintaining solid portfolio performance with minimal impairments. Committed to 42+ years of dividend growth, with Q3 dividend of $0.50/share.
- **Leadership Development**: Promoted key executives (Virgil Miller, Max Broden, Audrey Tillman) to strengthen succession planning for long-term growth.

**【CFO Financial Highlights】**
- **Japan Segment**: Adjusted EPS up 17.4% to $2.16, despite 10.5% decline in net earned premiums due to reinsurance transactions. Pretax margin improved to 44.7% (vs. 32.8% YoY), with benefit ratio down 15.9pts to 49.2%.
- **US Segment**: Net earned premiums +2.8% YoY, expense ratio down 260bps to 38.0% due to scale improvements. Pretax margin of 20.8% reflects strong underwriting performance.
- **Capital Management**: Repurchased $500M shares in Q3, maintaining liquidity of $3.9B. Leverage at 21% (target 20-25%) due to yen-dollar hedging program.
- **Risk Management**: Commercial real estate loan watch list at $1B, with $3M CECL reserve increase. Middle market loans performing better than expectations.

**【Q&A Key Takeaways】**
- **Japan Sales Strategy**: Tsumitas product driving 20-25% new customer mix, with plans to launch new cancer insurance product in Spring 2025. 50th anniversary marketing to boost cross-selling opportunities.
- **Capital Allocation**: Open to M&A or special dividends if stock price supports, but prioritizing buybacks (Q3: $500M) and dividend growth.
- **US Claims Trends**: Higher benefit ratio (+11.7pts YoY) due to group life scale growth (80s% benefit ratio) and intentional claims acceleration for policyholder value.
- **Succession Planning**: CEO Amos confident in bench strength, with Virgil Miller leading US transformation and Max Broden executing reinsurance strategy.


Actual																	1.2	1.27	1.39	1.05	1.53	1.59	1.56	1.33	1.48	1.55	1.23	1.4	1.55	1.58	1.84	1.28	1.66	1.83	2.16	1.56	1.66	1.78	2.49	1.57
Forecast																	1.1032	1.0535	1.1359	1.0463	1.2139	1.2763	1.3179	1.2629	1.3678	1.2781	1.2075	1.2143	1.4034	1.439	1.4903	1.4524	1.582	1.6006	1.689	1.6227	1.6674	1.7016	1.7718	1.6932
Surprise	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	+8.77%	+20.55%	+22.37%	+0.35%	+26.04%	+24.58%	+18.37%	+5.31%	+8.20%	+21.27%	+1.86%	+15.29%	+10.45%	+9.80%	+23.47%	-11.87%	+4.93%	+14.33%	+27.89%	-3.86%	-0.44%	+4.61%	+40.54%	-7.28%

Actual	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	5.16B	5.41B	5.67B	5.91B	5.87B	5.56B	5.24B	5.43B	5.27B	5.40B	4.82B	4.48B	4.80B	4.54B	4.51B	3.78B	5.44B	5.14B	4.33B	5.40B	4.33B	4.16B	4.74B	4.87B
Forecast	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	5.50B	5.49B	5.50B	5.50B	5.54B	5.36B	5.35B	5.23B	5.13B	4.80B	4.62B	4.50B	4.62B	4.47B	4.45B	4.40B	4.30B	4.25B	4.30B	4.33B	4.28B	4.33B	4.37B	4.25B
Surprise	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	-6.16%	-1.46%	+2.98%	+7.50%	+6.00%	+3.78%	-2.18%	+3.84%	+2.68%	+12.60%	+4.32%	-0.40%	+3.79%	+1.51%	+1.43%	-14.25%	+26.52%	+20.76%	+0.59%	+24.79%	+1.13%	-3.92%	+8.58%	+14.49%

AFL

AFL fundamentals

AFL Q4 2025 Earnings

Earnings Call

You can ask Aime

AFL

AFL fundamentals

AFL Q4 2025 Earnings

Earnings Call

AFL Earnings Call Summary for Q4/20258:00 AM on Feb 5, 2026

AFL Earnings Call Summary for Q3/20258:00 AM on Nov 5, 2025

AFL Earnings Call Summary for Q2/20258:00 AM on Aug 6, 2025

AFL Earnings Call Summary for Q1/20258:00 AM on May 1, 2025

AFL Earnings Call Summary for Q4/20248:00 AM on Feb 6, 2025

You can ask Aime